Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 16-23 , February 2010

Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma

  • Camillo Porta

      Affiliations

    • Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, Medical Oncology, IRCCS San Matteo University Hospital Foundation, Piazzale Camillo Golgi, 2I-27100 Pavia, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0382 501355.
    • ,
  • Joaquim Bellmunt

      Affiliations

    • Solid Tumour Oncology (Genitourinary and Gastrointestinal), Medical Oncology Service, Hospital Del Mar, Paseo Maritimo 25-29, Barcelona 08003, Spain
    • Tel.: +34 93 248 3137; fax: +34 93 248 3366.
    • ,
  • Tim Eisen

      Affiliations

    • University of Cambridge, Department of Oncology, Box 193 (R4), Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
    • Tel.: +44 1223 769312; fax: +44 1223 769313.
    • ,
  • Cezary Szczylik

      Affiliations

    • Department of Oncology, Central Clinical Hospital, Military Institute of Medicine, Ul. Szaserow 128, 00-909 Warsaw, Poland
    • Tel./fax: +48 22 6103088.
    • ,
  • Peter Mulders

      Affiliations

    • Department of Urology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, Geert Groteplein 10, NL 6500 HB Nijmegen, The Netherlands
    • Tel./fax: +31 24 3613735.

Received 27 July 2009 ,Revised 28 August 2009 ,Accepted 2 September 2009.

References 

  1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134
  2. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  3. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281
  4. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–2111
  5. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297:1233–1240
  6. Rawlins M. Harveian Oration. De testimonio: On the evidence for decisions about the use of therapeutic interventions. <www.rcplondon.ac.uk/pubs>; 2008 [accessed 11.08].
  7. Djulbegovic B, Loughran TPJ, Hornung CA, et al. The quality of medical evidence in haematology–oncology. Am J Med. 1999;106:198–205
  8. Nexavar summary of product characteristics. <http://www.emea.europa.eu/humandocs/PDFs/EPAR/nexavar/H-690-PI-en.pdf>; 2009 [accessed 15.05.09].
  9. Sutent summary of product characteristics. <http://www.emea.europa.eu/humandocs/PDFs/EPAR/sutent/H-687-PI-en.pdf>; 2009 [accessed 15.05.09].
  10. Torisel summary of product characteristics. <http://www.emea.europa.eu/humandocs/PDFs/EPAR/torisel/H-799-PI-en.pdf>; 2009 [accessed 15.05.09].
  11. Avastin summary of product characteristics. <http://www.emea.europa.eu/humandocs/PDFs/EPAR/avastin/H-582-PI-en.pdf>; 2009 [accessed 15.05.2009].
  12. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835–844
  13. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;[PMID: 19451442]
  14. Motzer RA, Hutson TE, Tomczac P, et al. Overall survival and updated results for sunitinib compared with interferon (IFN)-alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;[PMID: 19487381]
  15. Escudier BJ, Bellmunt J, Negrier S, et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009;27:15s [suppl; abstr 5020].
  16. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: calgb 90206. J Clin Oncol. 2008;26:5422–5428
  17. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–456
  18. National Comprehensive Guidelines Network. Kidney cancer. <http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf>; 2009 [accessed 05.05.09].
  19. Ljungberg B, Hanbury DC, Kuczyk MA, et al. European Association of Urology guidelines on renal cell carcinoma 2008. <http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/RCC.pdf>; 2009 [accessed 15.05.09].
  20. Beck J, Bajetta E, Escudier B, et al. A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Presentation at ECCO 14 2007, Barcelona, Spain; 2007.
  21. Knox JJ, Figlin RA, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. Presentation at ASCO 2007, Chicago, IL, USA. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=34297>; 2009 [accessed 15.05.09].
  22. Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. Presentation at ASCO 2007, Chicago, IL, USA. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32318>; 2009 [accessed 15.05.09].
  23. Delahunt B, Bethwaite PB, Nacey JN. Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype. Pathology. 2007;39:459–465
  24. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170:2163–2172
  25. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20:2376–2381
  26. Henderson CA, Bukowski RM, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: subset analysis of patients (pts) with brain metastases (BM). J Clin Oncol 2007;25(Suppl.):650s [Abstract 15506].
  27. Plimack ER, Jonasch E, Bekele BN, Smith LA, Araujo JC, Tannir NM. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): a phase II study. J Clin Oncol 2008;26(Suppl.):277s [Abstract 5112].
  28. Dutcher JP, de Souza PL, Figlin R, et al. Effect of temsirolimus versus interferon-a on survival of patients with advanced renal cell carcinoma of different tumour histologies. ASCO GI 2008. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20205>; 2009 [accessed 15.05.09].
  29. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20:2376–2381
  30. Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Ku JH. Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. Tumori. 2007;93:68–74
  31. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–2540
  32. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1280–1289
  33. Cho KS, Choi YD, Kim SJ, et al. A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma. Yonsei Med J. 2008;49:451–458
  34. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110:543–550
  35. Thyavihally YB, Mahantshetty U, Chamarajanagar RS, Raibhattanavar SG, Tongaonkar HB. Management of renal cell carcinoma with solitary metastasis. World J Surg Oncol. 2005;3:48
  36. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973–2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–2872
  37. Hariharan S, Szczylik C, Bracarda S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial. Presentation at ASCO 2008, Chicago, IL, USA. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34720> ; 2008 [accessed 15.05.09].
  38. Massard C, Zonierek J, Laplanche A, Schwartz B, Szczylik C, Escudier B. Incidence of brain metastasis in advanced renal cell carcinoma among patients randomized in a phase III trial of sorafenib, an oral multi-kinase inhibitor. In: Poster presentation at ESMO 2006, Istanbul, Turkey; 2006 [Abstract 454P].
  39. Motzer RJ, Figlin RA, Hutson TE, et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. Presentation at ASCO 2007, Chicago, IL, USA. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32015>; 2009 [accessed 15.05.09].
  40. Heng DY, Xie W, Regan M, et al. Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: results from a large multicenter study. Presentation at ASCO Genitourinary Cancers Symposium 2009. <http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=64&abstractID=20064>; 2009 [accessed 10.06.09, abstract 284].
  41. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649–1657
  42. Mekhail TM, bou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23:832–841
  43. Aapro MS, Kohne CH, Cohen HJ, Extermann M. Never too old? Age should not be a barrier to enrolment in cancer clinical trials. Oncologist. 2005;10:198–204
  44. Bellmunt J, Negrier S, Escudier B, Awada A, Aapro M. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG taskforce. Crit Rev Oncol Hematol. 2009;69:64–72
  45. Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol. 2008;54:133–140
  46. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10:757–763
  47. Bajetta E, Ravaud A, Bracada S, et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) >65 years with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008;26(Suppl.):273s [Abstract 5095].
  48. Dutcher JP, Szczylik C, Tannir N, et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). Presentation at ASCO 2007, Chicago, IL, USA. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=35666>; 2009 [accessed 15.05.09].
  49. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53:917–930
  50. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655
  51. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 199–205.
  52. Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol. 1999;52:1131–1136
  53. Grunwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie. 2007;30:519–524
  54. Laber DA. Risk factors, classification, and staging of renal cell cancer. Med Oncol. 2006;23:443–454
  55. Maroto-Rey P, Villavincencio H. Sorafenib: tolerance in patients on chronic haemodialysis. Oncology. 2008;74:245–246
  56. Khosravan R, Toh M, LaFargue J, Ni G, Bello C. Sunitinib pharmacokinetic (PK) and safety data in subjects with renal impairment and on hemodialysis. J Clin Oncol. 2008;26(Suppl.):131s;[Abstract 2578]
  57. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83–95
  58. Rathmell K, Amin C, Wallen E, Pruthi R. Neoadjuvant therapy with sorafenib for locally advanced renal cell carcinoma (RCC). ASCO GU 2008. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20383>; 2009 [accessed 15.05.09].
  59. Negrier S, Perol D, Ravaud A, et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J Clin Oncol 2005;23(Suppl.):380s [Abstract 4511].
  60. Proleukin summary of product characteristics. <http://emc.medicines.org.uk/medicine/19322/SPC/Proleukin/>; 2009 [accessed 15.05.09].
  61. Roferon-A summary of product characteristics. <http://emc.medicines.org.uk/medicine/1730/SPC/Roferon-A+Pre-Filled+Syringe/>; 2009 [accessed 15.05.09].
  62. Maroto-Rey P, Bellmunt J, Trigo JM, et al. First-line phase II trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment. J Clin Oncol 2007;25(Suppl.):661s [Abstract 15640].
  63. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505–2512
  64. Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol 2007;25(Suppl.):261s [Abstract 2506].
  65. Sablin MP, Negrier S, Ravaud A, et al. Sequential use of sorafenib and sunitinib in renal cancer. J Urol. 2009;182:29–34
  66. Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008;26(Suppl.):280s [Abstract 5123].
  67. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2008;179:81–86
  68. Rini BI. Clinical prognostic and predictive markers for metastatic RCC therapeutic choices. Presentation at ASCO 2008, Chicago, IL, USA. <http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=55&sessionID=36>; 2009 [accessed 15.05.09].
  69. Bukowski R, Cella D, Gondek K, Escudier B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol. 2007;30:220–227
  70. Parasuraman S, Hudes G, Levy D, et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-α (IFN) or the combination of IFN+TEMSR. J Clin Oncol 2007;25(Suppl.):247s [Abstract 5049].

PII: S0305-7372(09)00127-3

doi: 10.1016/j.ctrv.2009.09.001

Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 16-23 , February 2010

Article Tools

* Image Usage & Resolution